Amylyx Pharmaceuticals Inc (AMLX)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Amylyx Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.

Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead program, avexitide, is a GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035 for Wolfram syndrome, AMX0114 for ALS, and AMX0318 for post-bariatric hypoglycemia.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Amylyx Pharmaceuticals Inc stock.

Our verdict on AMLX

Not valued: We cannot value this company yet.

ETFs with the most weight in AMLX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than AMLX in Drug Manufacturers - Specialty & Generic

33 more in this industry show a wider margin of safety.

Is AMLX undervalued or overvalued?

We do not publish a verdict on AMLX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of AMLX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.